



# FINANCIAL TEAR SHEET

## CORPORATE PROFILE

The mission of CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. Our multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. In addition to our fully-owned programs, we have established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in other diseases with high unmet need. We have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from our scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. We are headquartered in Zug, Switzerland with R&D operations in Cambridge, Massachusetts, USA and some business operations in London, United Kingdom.

## PRIMARY IR CONTACT


Chris Brinzey  
Westwicke Partners  
**Phone:** 339-970-2843  
**E-mail:**  
chris.brinzey@westwicke.com

## STOCK PERFORMANCE

### CRSP (Common Stock)

<b>Exchange</b>	NASDAQ (US Dollar)
<b>Price</b>	<b>\$19.09</b>
<b>Change (%)</b>	▲ 0.05 (0.26%)
<b>Volume</b>	331,263
<b>52 Week Low</b>	\$11.63
<b>Market Cap</b>	\$781,008,462
<b>Rolling EPS</b>	-0.32
<b>PE Ratio</b>	0
<b>Shares Outstanding</b>	41,019,352

Data as of 11/21/17 4:00 p.m. ET



## RECENT HEADLINES & EVENTS

Nov-13-2017 - 8:01 a.m.  
CRISPR Therapeutics Announces Appointment of Michael Tomsicek as Chief Financial Officer

There are currently no events scheduled.

Nov-13-2017 - 5:00 a.m.  
CRISPR Therapeutics and Casebia Collaborate with CureVac on mRNA for Gene-Editing Programs

Nov-10-2017 - 8:00 p.m.  
CRISPR Therapeutics Highlights New Additions to Portfolio of Allogeneic CRISPR-based CAR-T Therapies at SITC Annual Meeting

## SEC FILINGS

<b>Filing Date</b>	<b>Form</b>
11/14/17	4
11/13/17	3
11/13/17	8-K
11/09/17	S-3

*Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources*